160 related articles for article (PubMed ID: 30207027)
1. Rituximab for the treatment of autoimmune subepidermal blistering diseases.
Riquelme-Mc Loughlin C; Estrach T; Morgado-Carrasco D; Fustà-Novell X; Riera-Monroig J; Iranzo P
Dermatol Ther; 2018 Sep; 31(5):e12687. PubMed ID: 30207027
[No Abstract] [Full Text] [Related]
2. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for autoimmune blistering diseases: recent studies, new insights.
Lunardon L; Payne AS
G Ital Dermatol Venereol; 2012 Jun; 147(3):269-76. PubMed ID: 22648328
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of rituximab in autoimmune blistering diseases.
Ahmed AR; Shetty S
Am J Clin Dermatol; 2015 Jun; 16(3):167-77. PubMed ID: 25791770
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
6. Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions.
Alaibac M
Front Immunol; 2018; 9():810. PubMed ID: 29720979
[No Abstract] [Full Text] [Related]
7. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations.
Ahmed AR; Aksoy M
Front Immunol; 2021; 12():727520. PubMed ID: 34646266
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study.
Mahmoudi H; Farid AS; Nili A; Dayani D; Tavakolpour S; Soori T; Teimourpour A; Isazade A; Abedini R; Balighi K; Daneshpazhooh M;
J Am Acad Dermatol; 2021 Apr; 84(4):1098-1100. PubMed ID: 33359593
[No Abstract] [Full Text] [Related]
9. Practice and Educational Gaps in Blistering Disease.
Ehsani-Chimeh N; Marinkovich MP
Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and its use in autoimmune bullous disorders.
Daniel BS; Murrell DF; Joly P
Immunol Allergy Clin North Am; 2012 May; 32(2):331-7, viii. PubMed ID: 22560146
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in Subepidermal Blistering Diseases.
Tan WH; Sim J; Sultana R; Lee HY
Dermatology; 2023; 239(1):5-11. PubMed ID: 36302346
[TBL] [Abstract][Full Text] [Related]
14. Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab.
Jensen AØ; Møller BK; Vangkilde A; Mark B; Obitz ER; Kragballe K; Iversen L
Br J Dermatol; 2009 Jun; 160(6):1359-61. PubMed ID: 19416252
[No Abstract] [Full Text] [Related]
15. [Autoimmune blistering skin diseases: recent advances].
Joly P
Presse Med; 2010 Oct; 39(10):1040-1. PubMed ID: 20692800
[No Abstract] [Full Text] [Related]
16. The safety of rituximab for the treatment of autoimmune blistering diseases: A systematic review.
Mohammed A; Hekman D; Li W; Misquith C; Rahnama-Moghadam S
J Am Acad Dermatol; 2022 Jun; 86(6):1439-1444. PubMed ID: 34214623
[No Abstract] [Full Text] [Related]
17. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
[TBL] [Abstract][Full Text] [Related]
18. Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases.
Gerber V; Velay A; Boehn L; Solis M; Kaeuffer C; Rougier E; Ursenbach A; Hansmann Y; Lefebvre N; Danion F; Ruch Y
J Med Virol; 2021 Jul; 93(7):4141-4144. PubMed ID: 33666242
[No Abstract] [Full Text] [Related]
19. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
[TBL] [Abstract][Full Text] [Related]
20. Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases.
van Beek N; Dähnrich C; Johannsen N; Lemcke S; Goletz S; Hübner F; Di Zenzo G; Dmochowski M; Drenovska K; Geller S; Horn M; Kowalewski C; Medenica L; Murrell DF; Patsatsi A; Uzun S; Vassileva S; Zillikens D; Schlumberger W; Schmidt E
J Am Acad Dermatol; 2017 May; 76(5):889-894.e5. PubMed ID: 28038887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
